Gosset Enthera Pharmaceuticals General Information
Enthera Pharmaceuticals has completed a Phase 1a trial of its lead candidate Ent001 in healthy volunteers with positive safety results and has initiated a Phase 1b trial in patients with moderately to severely active ulcerative colitis. The company’s approach aims to restore organ function by re-establishing stem cell capabilities via inhibition of the IGFBP3/TMEM219 apoptosis pathway. Preclinical data support potential efficacy in both T1D and IBD, with plans to expand into additional indications such as fibrotic diseases. The company’s programs are protected by a broad patent portfolio and supported by strong academic collaborations.
Contact Information
Italy
Drug Pipeline
Key Partnerships
Academic partnerships with Boston Children’s Hospital/Harvard Medical School, University of Milan, San Raffaele Hospital, Investors include Sofinnova Partners, AbbVie Ventures, Roche Venture Fund, JDRF T1D Fund
Enthera Pharmaceuticals Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Jul 29, 2020 | $28.0M | Completed | Phase 1 |